Korea University Research and Business Foundation; Sejong Campus
发明人:
Ki Yong LEE,Young Ho JEON,Youngjoo BYUN,Kiho LEE,Yong Woo JUNG
申请号：
US16473354
公开号：
US20200121634A1
申请日:
2018.01.04
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to a pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy including baicalein as an active ingredient. Baicalein is capable of regulating thymic stromal lymphopoietin-mediated signal transduction. The pharmaceutical composition of the present invention can effectively suppress inflammatory responses of allergic or asthmatic diseases due to the presence of baicalein extracted from Scutellariae Radix that regulates TSLP-mediated intracellular signal transduction to inhibit intracellular phosphorylation of STATS and inhibit the binding of TSLP to TSLPR. In addition, the pharmaceutical composition of the present invention may further include one or more compounds having synergistic effects with baicalein. In this case, the pharmaceutical composition can more effectively suppress inflammatory responses of allergic diseases such as asthma or atopy.
